Semaglutide: A Comprehensive Review of its Efficacy and Safety for Obesity

Obesity is a complex, chronic disease affecting millions worldwide, significantly increasing the risk of conditions like type 2 diabetes, cardiovascular disease, and certain cancers. Traditional weight loss interventions often struggle with long-term efficacy, highlighting an urgent need for effective pharmacological treatments. This narrative review synthesizes the current evidence on Semaglutide, a GLP-1 receptor agonist, to provide a comprehensive understanding of its role in obesity management, its safety profile, and future therapeutic directions, thereby addressing the current understanding of Semaglutide's overall impact and potential in clinical practice.

The review consistently demonstrated Semaglutide's robust efficacy in promoting significant weight loss across various patient cohorts. In pivotal trials, patients receiving Semaglutide 2.4 mg weekly achieved a mean total body weight loss of 15% to 17% over 68 weeks, compared to 2-3% with placebo. This translated to over 60% of patients achieving a 5% or greater weight reduction, and over 30% achieving 15% or greater. Common adverse events were primarily gastrointestinal, with nausea reported by 70%, diarrhea by 40%, and vomiting by 25% of participants, generally mild to moderate and transient. Beyond weight loss, the review highlighted Semaglutide's beneficial effects on cardiometabolic markers, including reductions in HbA1c, blood pressure, and lipid profiles. The most significant finding was that Semaglutide consistently achieved a mean total body weight loss of 15% to 17% in individuals with obesity, significantly outperforming placebo by an average of 12-14 percentage points.